EUVIMEDEUVIMED entdecken
Crossref

Pharmacokinetic study of the interaction between luteolin and magnoflorine in rats

Lu Liu, Xiaohua Li

Chemical Biology & Drug Design · 2024

DOI: 10.1111/cbdd.14356 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2024. Verfasst von Lu Liu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrine, Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Luteolin, Cytochrome P-450 CYP3A, Aporphines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: This work was supported by Shanghai Pudong New Area Science and Technology Development Fund Special Project for People's Livelihood Scientific Research (Grant….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Both luteolin and magnoflorine have been reported to regulate the development of breast cancer, which makes them easier to co‐administrate. Luteolin was co‐administrated with magnoflorine to evaluate their potential interaction. The pharmacokinetic study was performed on male Sprague–Dawley rats randomly grouped as the single administration of luteolin and the co‐administration of luteolin and magnoflorine with six rats of each. CaCO‐2 cell transwell assay was employed for transport evaluation, and the metabolic stability of luteolin and CYP3A activity were assessed in rat liver microsomes. The effect of luteolin on MDA‐MB‐231 cells was assessed with CCK8 assay. Magnoflorine significantly changed the pharmacokinetic profile of luteolin with increased area under the curve (AUC), prolonged t 1/2 , and reduced clearance rate. Magnoflorine also suppressed the efflux ratio and improved the in vitro metabolic stability of luteolin. Magnoflorine also enhanced the inhibitory effect of luteolin on MDA‐MB‐231 cells. Magnoflorine significantly inhibited CYP3A activity with the IC 50 of 18.99 μM. Magnoflorine prolonged the system exposure, enhanced the metabolic stability, and enhanced the anti‐tumor effect of luteolin through inactivating CYP3A.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LuteolinCytochrome P-450 CYP3AAporphinesHumansRatsMaleAnimalsRats, Sprague-DawleyCaco-2 CellsMicrosomes, LiverDrug Interactions

Stichwörter der Autor:innen

CYP3AMagnoflorineluteolinpharmacokinetics

Substanzen

magnoflorineLuteolinCytochrome P-450 CYP3AAporphines

Autor:innen und Institutionen

  • Department of Endocrine, Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Förderung

  • This work was supported by Shanghai Pudong New Area Science and Technology Development Fund Special Project for People's Livelihood Scientific Research (Grant…

Zitieren

APA

Liu, L., & Li, X. (2024). Pharmacokinetic study of the interaction between luteolin and magnoflorine in rats. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.14356

Vancouver

Liu L, Li X. Pharmacokinetic study of the interaction between luteolin and magnoflorine in rats. Chemical Biology & Drug Design. 2024. doi:10.1111/cbdd.14356

BibTeX
@article{Liu2024,
  author = {Liu, Lu and Li, Xiaohua},
  title = {Pharmacokinetic study of the interaction between luteolin and magnoflorine in rats},
  journal = {Chemical Biology & Drug Design},
  year = {2024},
  doi = {10.1111/cbdd.14356}
}
Kostenlos starten →